SRZNW
Surrozen, Inc. NASDAQ$0.02
Mkt Cap $140,575
52w Low $0.01
59.4% of range
52w High $0.03
50d MA $0.02
200d MA $0.02
P/E (TTM)
0.0x
EV/EBITDA
-2.1x
P/B
—
Debt/Equity
-0.0x
ROE
128.9%
P/FCF
-5.6x
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
$0.02
200d MA
$0.02
Avg Volume
16.3K
About
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, s…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -1.29 | -19.13 | -1385.8% | 0.02 | +0.0% | +0.0% | +11.8% | +20.0% | -5.3% | +11.8% | — |
| Nov 7, 2025 | AMC | -1.14 | -8.36 | -636.5% | 0.02 | +22.1% | -18.2% | -25.3% | -38.3% | -9.7% | -5.2% | — |
| Aug 8, 2025 | AMC | -1.11 | 4.65 | +518.9% | — | — | — | — | — | — | — | — |
| May 9, 2025 | AMC | — | -7.43 | — | 0.02 | +30.4% | +30.4% | +30.0% | -1.3% | — | — | — |
| Sep 30, 2023 | AMC | — | -0.42 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.38 | — | 0.06 | -22.1% | -22.2% | -18.5% | -29.9% | — | — | — |
| Mar 31, 2023 | AMC | — | -0.47 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | — | 0.21 | — | — | — | — | — | — | — | — | — |
Data updated apr 28, 2026 9:51pm
· Source: massive.com